114 reports of this reaction
1.7% of all TOBRAMYCIN AND DEXAMETHASONE reports
#14 most reported adverse reaction
VISUAL IMPAIRMENT is the #14 most commonly reported adverse reaction for TOBRAMYCIN AND DEXAMETHASONE, manufactured by Novartis Pharmaceuticals Corporation. There are 114 FDA adverse event reports linking TOBRAMYCIN AND DEXAMETHASONE to VISUAL IMPAIRMENT. This represents approximately 1.7% of all 6,884 adverse event reports for this drug.
Patients taking TOBRAMYCIN AND DEXAMETHASONE who experience visual impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL IMPAIRMENT is a less commonly reported adverse event for TOBRAMYCIN AND DEXAMETHASONE, but still significant enough to appear in the safety profile.
In addition to visual impairment, the following adverse reactions have been reported for TOBRAMYCIN AND DEXAMETHASONE:
The following drugs have also been linked to visual impairment in FDA adverse event reports:
VISUAL IMPAIRMENT has been reported as an adverse event in 114 FDA reports for TOBRAMYCIN AND DEXAMETHASONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL IMPAIRMENT accounts for approximately 1.7% of all adverse event reports for TOBRAMYCIN AND DEXAMETHASONE, making it a notable side effect.
If you experience visual impairment while taking TOBRAMYCIN AND DEXAMETHASONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.